IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
IMP: Shining a spotlight on obesity treatment in NAFLD/NASH - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020
View
Metabolism, Alcohol & Toxicity
5
International Medical Press: Obesity management in NAFLD/NASH: can we do more? - Digital ILC 2020
